Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Beta interferon restricts the inflammatory potential of CD4 + cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells
Beta-interferon (IFN-β) is a valuable therapy for multiple sclerosis (MS) which is also effective in the animal model of experimental autoimmune encephalomyelitis (EAE). However, the accurate mechanisms to explain its anti-inflammatory activity in the disease are not fully revealed. Available data support that T lymphocytes are among the main cell targets of IFN-β. We have found that
in vitro anti-CD3 stimulation of uncommitted murine
naïve T cells under IFN-β treatment results in skewing the T cell differentiation process towards the T2 phenotype, in a prevention from apoptosis of naturally occurring CD4
+ T regulatory cells (nTreg) in correlation with an increase in Bcl-x
L expression, and in a decrease of IL-17 expression. Elimination of nTreg from the primary culture of
naïve CD4
+ cells abolished the down-regulation of IL-17 driven by IFN-β, what suggests the interaction between Th17 and nTreg subsets. Experiments in EAE induced in SJL mice, showed
in vivo evidence for the accumulation of spleen CD4
+CD25
+GITR
+Foxp3
+ cells after IFN-β treatment. On the other hand, treated animals showed a striking decrease of IL-17 expression by peripheral CD4
+ cells (Th17) and MBP-specific spinal cord cells. Both the
in vivo and
in vitro results point out new targets through which IFN-β could exert its therapeutic action.